// App-Quantinova.ai

: Late Breaking Abstract - Long-term safety of pirfenidone in a real-world setting: final results from the prospective, observational PASSPORT registry

Researchers

Presenter

  • Vincent Cottin

Principal Investigators

  • Dirk Koschel

  • Andreas Guenther

  • Carlo Albera

  • Arata Azuma

  • Magnus Skold

  • Sara Tomassetti

  • Philip Hormel

  • John L. Stauffer

  • Indiana Strombom

  • Klaus-Uwe Kirchgaessler

  • Toby M. Maher

Medical Centers

  • Department of Pulmonary Diseases, Fachkrankenhaus Coswig, Coswig, Germany.

  • Interstitial Lung Disease Clinic, University Hospital Giessen, Giessen, Germany

  • Dept of Clinical and Biological Sciences, University of Turin, Turin, Italy

  • Post-graduate School of Medicine, Pulmonary Medicine, Nippon Medical School, Tokyo, Japan

  • Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

  • GB Morgagni Hospital, Forlì, Italy

  • Genentech Inc., San Francisco, United States

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK

Locations

  • France

  • Germany

  • Italy

  • Japan

  • Sweden

  • United States

  • Switzerland

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved